With Simoa, Quanterix aims to detect oncology biomarkers for improved diagnostics and treatments, identify neurological biomarkers associated with brain injury and disease, predict cardiovascular events using cardiac biomarkers, measure inflammatory molecules for research purposes, and even fight against and treat COVID-19 by measuring cytokine levels. Their ultra-sensitive detection solution has the potential to revolutionize healthcare by enabling early disease detection, better prognosis, and precise treatment methods.